Chiesi Global Rare Diseases Launches Second Edition of Find For Rare to Advance LSD Research
Event summary
- Chiesi Global Rare Diseases will launch the second edition of Find For Rare at the 2026 ERA Congress in Glasgow, Scotland.
- The initiative supports research in Fabry disease, alpha-mannosidosis, and nephropathic cystinosis.
- Chiesi aims to advance understanding and care for lysosomal storage disorders (LSDs).
- The company will present real-world data on Fabry disease and nephropathic cystinosis at the congress.
The big picture
Chiesi Global Rare Diseases is reinforcing its commitment to LSDs through targeted research initiatives and scientific contributions. The launch of Find For Rare's second edition underscores the company's long-term strategy to support innovative research and improve care for rare disease communities. This aligns with broader industry trends toward specialized, patient-centric approaches in rare disease treatment.
What we're watching
- Research Impact
- How the second edition of Find For Rare will accelerate innovation in LSDs and translate into improved patient outcomes.
- Scientific Collaboration
- Whether Chiesi's focus on multidisciplinary coordination will enhance care for nephropathic cystinosis patients.
- Pipeline Development
- The pace at which Chiesi advances its emerging pipeline for rare kidney diseases, including primary hyperoxaluria type 1 (pH1).